Optimal Confidence Sets, Bioequivalence, and the Limaçon of Pascal
最优置信集合、生物等效性与帕斯卡蜗线AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要讨论通用置信集合决策理论与生物等效性,没有所列经济学领域的明确依据。
最优置信集合、生物等效性与帕斯卡蜗线AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
We begin with a decision-theoretic investigation into confidence sets that minimize expected volume at a given parameter value. Such sets are constructed by inverting a family of uniformly most powerful tests, and hence they also enjoy the optimality property of being uniformly most accurate. In addition, these sets possess Bayesian optimal volume properties and represent the first case (to our knowledge) of a frequentist 1 – α confidence set that possesses a Bayesian optimality property. The hypothesis testing problem that generates these sets is similar to that encountered in bioequivalence testing. Our sets are optimal for testing bioequivalence in certain settings; in the case of the normal distribution, the optimal set is a curve known as the limaçon of Pascal. We illustrate the use of these curves with a biopharmaceutical example.